Skip to content
Two Sigma Investments LP reduced their shares in Eyepoint Pharmaceuticals, Inc. (Nasdak: EyPT – Free report(22.6 % in the fourth quarter, according to the latest Form 13F file with SEC. The company owns 353,954 shares of the company after selling 103,098 shares during this period. Two Sigma Investments LP have about 0.52 % of EyePoint drugs worth $ 2,637,000 in its latest version of SEC.
Many other great investors have recently added to or reduced their classes in EyPT. SUVRETTA CAPITAL Management LLC raised its share in Eyepoint Pharmaceuticals by 31.1 % during the fourth quarter. SUVRETTA CAPITAL Management LLC now has 6,783,091 shares from the company’s shares of $ 50,534,000 after purchasing additional 1,607,268 shares during the last quarter. Adage Capital Partners GP LLC raised its share in Eyepoint Pharmaceuticals by 51.7 % during the fourth quarter. Adage Capital Partners GP LLC now has 5,750,000 shares of the company with a value of $ 42,838,000 after purchasing additional 1958,580 shares during the last quarter. Franklin Resources Inc. Its share is at Eyepoint Pharmaceuticals by 3.1 % during the fourth quarter. Franklin Resources Inc. Now 4,137,567 shares of the company’s shares of $ 30,825,000 after purchasing additional 125,519 shares during the last quarter. Vanguard Group Inc. Its share is at Eyepoint Pharmaceuticals by 24.8 % during the fourth quarter. Vanguard Group Inc. Now 3,803,227 shares of the company’s shares of $ 28,334,000 after purchasing additional 75,045 shares during the last quarter. Finally, I lifted Fedaged Hermes Inc. Its share is at Eyepoint Pharmaceuticals by 92.7 % during the fourth quarter. She owns Fedaged Hermes Inc. Now 3,707,445 shares of the company’s shares of $ 27,620,000 after purchasing 1,783,765 shares during the last quarter. Founding investors have 99.41 % of the company’s shares.
Wall Street Analyst weighs
Several stock research analysts have issued reports on EyPT shares. Sharadan Capital fell off its target price on Eyepoint Pharmaceuticals from $ 33.00 to $ 27.00 and a “purchase” classification of the company in a research note on Thursday, May 8. Wall Street Zen Eyepoint drugs were raised to the “Sale” classification in a research note on Friday, March 14th. Mizuho dropped its target price on Eyepoint Pharmaceuticals from $ 30.00 to $ 26.00 and put the company’s “Outperform” classification in a research note on Friday May 16. Finally, HC Wainwright confirmed again the “Buy” rating and set a $ 22.00 targeted price on Eyepoint Pharmaceuticals in a research note on Thursday. One of the stock research analysts classified the shared of the sale and issued nine company purchase. According to Marketbeat.com, at Eyepoint Pharmaceuticals, a consensus rating on “Buy Modra Buy” and a $ 25.38 consensus aim.
Get our latest analyzes on EyPT
Performing Eyepoint drugs
EyPT It opened at $ 7.21 on Friday. The market value is 496.13 million dollars, and the P/E ratio of -3.61 and Beta 1.58. The average price of commercial activity for 50 days is $ 5.86, and its average moving price for 200 days is $ 6.95. At Eyepoint Pharmaceuticals, Inc. The lowest level in 12 months at $ 3.91 and the highest level in 12 months at $ 13.99.
Eyepoint Pharmaceuticals (Nasdak: EyPT – Get a free reportThe latest results of its quarterly profits were announced on Wednesday, May 7. The company has reported ($ 0.65) profits per share (EPS) for a quarter, where estimates of the consensus of the analysts ($ 0.65) meet. Eyepoint pharmaceuticals has achieved a negative return on property rights 43.01 % and a negative net of 226.57 %. The company achieved revenues of $ 24.50 million per quarter, compared to the estimation of the consensus of $ 8.84 million. Stock Research analysts expect Eyepoint pharmaceuticals, Inc. Publish -2.13 profitability of the share for the current fiscal year.
About Eyepoint Pharmaceuticals
((Free report))
Eyepoint Pharmaceuticals, INC, a vital pharmaceutical company in the clinical stage, is participating in developing and marketing treatments to improve the lives of patients with serious retinal retinal diseases. The company’s pipeline works to take advantage of the Durasert E -Technology Technology for Biological Biology to deliver intra -eye medications.
Recommended stories
Do you want to see what other hedge boxes carry EyPT? Visit Holdingschaannel.com For the latest 13F files and interior trades for Eyepoint Pharmaceuticals, Inc. (Nasdak: EyPT – Free report).
Receive news and classifications for Eyepoint Pharmaceuticals daily Enter your email address below to receive a daily summary summary of the latest news and analyst classification for Eyepoint Pharmaceuticals and related companies with the free daily newsletter of Marketbeat.com.